胸腺肽-α1辅助抗结核化疗方案治疗肠结核的临床观察  

Thymosin-α1 combined with anti-tuberculosis chemotherapy in the treatment of intestinal tuberculosis

作　　者：霍丽丽 Huo Lili(Department of Prevention,Binzhou Tuberculosis Control Institute,Binzhou 251700,China)

机构地区：[1]山东省滨州市结核病防治院预防科,251700

出　　处：《中国实用医刊》2021年第13期94-97,共4页Chinese Journal of Practical Medicine

摘　　要：目的:探讨胸腺肽-α1辅助抗结核化疗方案治疗肠结核的效果。方法:抽取2018年5月至2019年9月滨州市结核病防治院收治的肠结核患者92例,采用随机数字奇偶法分组,奇数纳入观察组(46例),偶数纳入对照组(46例)。对照组采用常规抗结核化疗方案,基于此,观察组采用胸腺肽-α1辅助抗结核化疗方案治疗。比较两组炎症指标、免疫指标及肠黏膜功能及不良反应发生率。结果:治疗后,观察组肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组T淋巴细胞亚群CD3+、CD4+、CD8+以及自然杀伤细胞(NK细胞)水平高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组D-乳酸、二胺氧化酶水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论:胸腺肽-α1辅助抗结核化疗方案治疗肠结核效果较好,可有效减轻患者炎性反应,增强机体免疫力,改善肠黏膜功能,且安全性较高。Objective To investigate the effect of thymosin-α1 combined with anti-tuberculosis chemotherapy on intestinal tuberculosis.Methods A total of 92 patients with intestinal tuberculosis admitted to Binzhou Tuberculosis Control Institute from May 2018 to September 2019 were selected and divided into two groups by random number odd even method.The patients with odd number were included in the observation group(46 cases),and the patients with even number were included in the control group(46 cases).The control group received conventional anti-tuberculosis chemotherapy,while the observation group combined with thymosin-α1 adjuvant therapy.The inflammatory index,immune index,intestinal mucosal function and incidence of adverse reactions were compared between the two groups.Results After treatment,the levels of tumor necrosis factor-α(TNF-α)and C-reactive protein(CRP)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of T lymphocyte subsets cluster of differentiation(CD)3+,CD4+,CD8+and natural kill(NK)cells in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of D-lactic acid and diamine oxidase of observation group were lower than those of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Thymosin-α1 combined with anti-tuberculosis chemotherapy is effective in the treatment of intestinal tuberculosis,which can effectively reduce the inflammatory reaction of patients,enhance immunity,improve intestinal mucosal function,and has high safety.

关 键 词：肠结核 胸腺肽-Α1 抗结核化疗方案 

分 类 号：R524[医药卫生—内科学]